FDA Accepts Supplement Application for CRYSVITA (BUROSUMAB-TWZA)
The FDA has accepted a supplemental application for CRYSVITA (BUROSUMAB-TWZA) from Kyowa Kirin.
Asset / Drug
Drug and asset intelligence for CRYSVITA with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.